ProCE Banner Activity

PROTAC ER Degraders in ER+/HER2- MBC Progressing After Endocrine Therapy: Current Treatment Landscape and Unmet Needs for Patients

Slideset

Download these slides for information on current treatment options for patients with ER+/HER2- MBC who experience disease progression after endocrine therapy, with a focus on novel therapies in the post-CDK4/6 inhibitor setting.

Released: November 19, 2024

Expiration: November 18, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.